Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi). Methods Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months. Results A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries was observed. Twelve-month retention was 80% (95% C...
Objective: To investigate whether axial spondyloarthritis (axSpA) patients with extremely poor patie...
To access publisher's full text version of this article click on the hyperlink belowObjectives: To i...
Acknowledgements Thanks to Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration. No...
Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA...
OBJECTIVE To study drug retention and response rates in patients with axial spondyloarthritis (ax...
To access publisher's full text version of this article click on the hyperlink belowOBJECTIVE: To s...
Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA...
Objectives: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondy...
OBJECTIVES: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis f...
Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis f...
Objectives: To investigate time trends in baseline characteristics and retention, remission and resp...
Objectives To investigate time trends in baseline characteristics and retention, remission and respo...
OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and resp...
OBJECTIVES To investigate time trends in baseline characteristics and retention, remission and re...
OBJECTIVE To investigate the distribution of patient-reported outcomes (PROs) in patients with ax...
Objective: To investigate whether axial spondyloarthritis (axSpA) patients with extremely poor patie...
To access publisher's full text version of this article click on the hyperlink belowObjectives: To i...
Acknowledgements Thanks to Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration. No...
Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA...
OBJECTIVE To study drug retention and response rates in patients with axial spondyloarthritis (ax...
To access publisher's full text version of this article click on the hyperlink belowOBJECTIVE: To s...
Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA...
Objectives: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondy...
OBJECTIVES: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis f...
Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis f...
Objectives: To investigate time trends in baseline characteristics and retention, remission and resp...
Objectives To investigate time trends in baseline characteristics and retention, remission and respo...
OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and resp...
OBJECTIVES To investigate time trends in baseline characteristics and retention, remission and re...
OBJECTIVE To investigate the distribution of patient-reported outcomes (PROs) in patients with ax...
Objective: To investigate whether axial spondyloarthritis (axSpA) patients with extremely poor patie...
To access publisher's full text version of this article click on the hyperlink belowObjectives: To i...
Acknowledgements Thanks to Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration. No...